Table 2

Crude, adjusted and imputed HR rate with 95% CI for the combined outcome: acute myocardial infarction (ICD-10: MI2), ischaemic stroke (ICD-10: I63), unspecified stroke (ICD-10: I64), coronary artery bypass grafting (ICD-10 code: I25.810), percutaneous coronary intervention (ICD-10 code: I21.A9) and all-cause mortality among 42 257 patients undergoing their first non-contrast-enhanced cardiac CT examination due to incident chest pain in Denmark, 2008–2016

ExposureNEvents in follow-upRate per 1000
person-years (95% CI)
HR, crude
(95% CI)
HR, adjusted*
(95% CI)
Imputed†
95% CI
Overall
 Not RA41 899205214.0 (13.4 to 14.6)111
 RA3582824.4 (16.8 to 35.3)1.75 (1.21 to 2.54)1.31 (0.90 to 1.91)1.35 (0.93 to 1.96)
Serology
 Not RA41 899205214.0 (13.4 to 14.6)111
 Seropositive RA2802224.9 (16.4 to 37.8)1.79 (1.20 to 2.72)1.41 (0.92 to 2.14)1.42 (0.93 to 2.16)
 Other RA78622.7 (10.2 to 50.4)1.62 (0.73 to 3.61)1.35 (0.60 to 3.02)1.15 (0.51 to 2.56)
Flare treatment
 Not RA41 899205214.0 (13.4 to 14.6)111
 No joint injection‡2151318.9 (11.0 to 32.6)1.35 (0.79 to 2.34)1.22 (0.69 to 2.15)1.05 (0.61 to 1.81)
 ≥1 joint injections§1431532.4 (19.6 to 53.8)2.34 (1.41 to 3.89)1.62 (0.92 to 2.85)1.80 (1.08 to 3.00)
Treatment escalation
 Not RA41899205214.0 (13.4 to 14.6)111
 csDMARD2572226.7 (17.6 to 40.6)1.92 (1.26 to 2.91)1.42 (0.91 to 2.24)1.38 (0.91 to 2.11)
 bDMARD**101618.4 (8.30 to 41.0)1.33 (0.59 to 2.95)1.27 (0.53 to 3.05)1.25 (0.56 to 2.79)
  • *Adjusted for sex, age, comorbidity, hypertension, lipid-lowing treatment, BMI, smoking

  • † Imputation of missing values for BMI and smoking.

  • ‡0 joint injection within 3 years prior to cardiac CT.

  • §≥1 joint injection within 3 years prior to cardiac CT.

  • ¶Patients exclusively treated with csDMARDs.

  • **Patients treated with a bDMARD at any time during the course of disease.

  • bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMAD, conventional synthetic disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.